Embla Medical hf: Share Buyback Program Completed
Announcement no. 60/2025
23 December 2025
Reykjavik, Iceland/Copenhagen, Denmark, 23 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the completion of the share buyback program, which was announced in Company Announcement no. 3/2025 dated 7 February 2025. Following are the last transactions carried out under the current share buyback program.
| Transaction date | No. of shares | Avg. purchase price in DKK | Transaction value in DKK | |
| 22 December 2025 | 5,000 | 33.70 | 168.500 |
The purpose of the Program was to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy. Embla Medical could acquire 2,000,000 shares under the Program for total consideration not exceeding USD 10 million up until and including December 31, 2025.
Embla Medical acquired 1,987,027 shares under the Program at an average price of DKK 32.00. Following the last transactions, Embla Medical currently holds 2,673,596 shares, corresponding to 0.62% of the Company’s total share capital.
The Program on Nasdaq Copenhagen was carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission’s delegated regulation 2016/1052.
Further information
Klaus Sindahl, Head of Investor Relations, [email protected], +45 5363 0134
Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors
About Embla Medical
Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women’s Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com